https://novapharmanews.com/us/news/cdc-ebola-outbreak-central-africa-20000-cases-2026 2026-06-06T10:37:20.110Z NovaPharmaNews en 2026-06-06T10:31:46.119Z CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures Ebola https://novapharmanews.com/uploads/articles/cdc-ebola-outbreak-central-africa-20000-cases-2026.webp CDC: Ebola outbreak in Central Africa could reach 20,000 cases without strong countermeasures https://novapharmanews.com/apac/news/nmpa-china-fda-drug-approval-2026-pathways-timelines-impact 2026-06-06T10:35:45.935Z NovaPharmaNews en 2026-06-06T02:39:40.146Z NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact https://novapharmanews.com/uploads/articles/nmpa-china-fda-drug-approval-2026-pathways-timelines-impact.webp NMPA China FDA Drug Approval: 2026 Pathways, Timelines & Impact https://novapharmanews.com/eu/news/maersk-europe-market-update-june-2026-pharma-supply-chains 2026-06-06T10:07:43.552Z NovaPharmaNews en 2026-06-06T02:31:36.791Z Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains https://novapharmanews.com/uploads/articles/maersk-europe-market-update-june-2026-pharma-supply-chains.webp Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains https://novapharmanews.com/eu/news/regulatory-round-up-2-february-2026 2026-06-06T10:07:17.871Z NovaPharmaNews en 2026-06-06T02:25:30.373Z Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma https://novapharmanews.com/uploads/articles/regulatory-round-up-2-february-2026.webp Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma https://novapharmanews.com/us/news/fda-issues-june-2026-guidance-gene-therapy-payor-comms-cmc-flexibilities 2026-06-06T10:07:19.406Z NovaPharmaNews en 2026-06-06T02:20:36.797Z FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities https://novapharmanews.com/uploads/articles/fda-issues-june-2026-guidance-gene-therapy-payor-comms-cmc-flexibilities.webp FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities https://novapharmanews.com/us/news/friday-five-asco-takeaways-ada-china-deals-clinical-trials 2026-06-06T10:07:21.566Z NovaPharmaNews en 2026-06-06T02:03:30.642Z Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials https://novapharmanews.com/uploads/articles/friday-five-asco-takeaways-ada-china-deals-clinical-trials.webp Friday Five: ASCO Takeaways, ADA Focus, China Deals & More – Clinical Trials https://novapharmanews.com/us/news/pharmalittle-roche-blackmail-skinny-labels-supreme-court 2026-06-06T10:07:35.325Z NovaPharmaNews en 2026-06-06T01:58:04.550Z Pharmalittle: Roche accuses U.S. of 'blackmail,' Supreme Court rules on skinny labels https://novapharmanews.com/uploads/articles/pharmalittle-roche-blackmail-skinny-labels-supreme-court.webp Pharmalittle: Roche accuses U.S. of 'blackmail,' Supreme Court rules on skinny labels https://novapharmanews.com/us/news/ebola-2026-us-response-travel-restrictions-debate 2026-06-06T10:07:25.241Z NovaPharmaNews en 2026-06-06T01:58:04.009Z Ebola 2026: US Response and Travel Restrictions Debate Ebola https://novapharmanews.com/uploads/articles/ebola-2026-us-response-travel-restrictions-debate.webp Ebola 2026: US Response and Travel Restrictions Debate https://novapharmanews.com/us/news/senior-nih-official-pushes-maha-strategy-to-skeptical-ada-audience 2026-06-06T03:15:26.388Z NovaPharmaNews en 2026-06-06T01:58:03.454Z Senior NIH official pushes MAHA strategy to skeptical ADA audience https://novapharmanews.com/uploads/articles/senior-nih-official-pushes-maha-strategy-to-skeptical-ada-audience.webp Senior NIH official pushes MAHA strategy to skeptical ADA audience https://novapharmanews.com/us/news/newer-glp-1s-pushback-research-cuts-protest 2026-06-06T06:03:39.593Z NovaPharmaNews en 2026-06-06T01:58:02.704Z STAT+: Newer GLP-1s, pushback on research cuts, and a protest GLP-1 https://novapharmanews.com/uploads/articles/newer-glp-1s-pushback-research-cuts-protest.webp STAT+: Newer GLP-1s, pushback on research cuts, and a protest https://novapharmanews.com/us/news/abivax-colitis-drug-hits-goal-cancer-cases-rattle-investors 2026-06-06T03:17:07.173Z NovaPharmaNews en 2026-06-06T01:52:33.404Z Abivax colitis drug hits goal, but cancer cases rattle investors colitis https://novapharmanews.com/uploads/articles/abivax-colitis-drug-hits-goal-cancer-cases-rattle-investors.webp Abivax colitis drug hits goal, but cancer cases rattle investors https://novapharmanews.com/us/news/supreme-court-sides-with-generic-drug-maker-icosapent-ethyl 2026-06-06T05:29:52.381Z NovaPharmaNews en 2026-06-06T01:24:07.937Z Supreme Court sides with generic drug maker in icosapent ethyl patent case icosapent ethyl, severe hypertriglyceridemia https://novapharmanews.com/uploads/articles/supreme-court-sides-with-generic-drug-maker-icosapent-ethyl.webp Supreme Court sides with generic drug maker in icosapent ethyl patent case https://novapharmanews.com/eu/news/baker-company-benelux-joins-europabio-cell-culture-lab-safety 2026-06-06T10:07:15.433Z NovaPharmaNews en 2026-06-06T00:50:45.729Z The Baker Company Benelux BV joins EuropaBio: Advancing cell culture and lab safety technologies https://novapharmanews.com/uploads/articles/baker-company-benelux-joins-europabio-cell-culture-lab-safety.webp The Baker Company Benelux BV joins EuropaBio: Advancing cell culture and lab safety technologies https://novapharmanews.com/us/news/rx-rundown-pfizer-hikma-newlimit-drug-approvals-catalyst-tracker 2026-06-06T01:26:20.060Z NovaPharmaNews en 2026-06-05T23:41:15.849Z Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker https://novapharmanews.com/uploads/articles/rx-rundown-pfizer-hikma-newlimit-drug-approvals-catalyst-tracker.webp Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker https://novapharmanews.com/us/news/mira-pharmaceuticals-global-rights-mira-55-skny-1 2026-06-06T03:47:29.079Z NovaPharmaNews en 2026-06-05T23:37:56.541Z MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1 MIRA-55, SKNY-1 https://novapharmanews.com/uploads/articles/mira-pharmaceuticals-global-rights-mira-55-skny-1.webp MIRA Pharma Consolidates Global Rights to MIRA-55 and SKNY-1 https://novapharmanews.com/us/news/4-biotech-stocks-investors-should-watch-in-2026-market-analysis 2026-06-06T10:06:56.619Z NovaPharmaNews en 2026-06-05T23:12:37.958Z 4 Biotech Stocks Investors Should Watch in 2026: Market Analysis https://novapharmanews.com/uploads/articles/4-biotech-stocks-investors-should-watch-in-2026-market-analysis.webp 4 Biotech Stocks Investors Should Watch in 2026: Market Analysis https://novapharmanews.com/us/news/alabama-board-medical-examiners-warning-non-fda-approved-peptides 2026-06-06T10:06:58.678Z NovaPharmaNews en 2026-06-05T22:35:50.773Z Alabama Board of Medical Examiners Issues Warning on Non-FDA-Approved Peptides: What Pharma Teams Need to Know https://novapharmanews.com/uploads/articles/alabama-board-medical-examiners-warning-non-fda-approved-peptides.webp Alabama Board of Medical Examiners Issues Warning on Non-FDA-Approved Peptides: What Pharma Teams Need to Know https://novapharmanews.com/us/news/vertex-fda-accepts-bla-povetacicept-iga-nephropathy-accelerated-approval 2026-06-06T01:53:24.860Z NovaPharmaNews en 2026-06-05T22:17:18.196Z Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy Povetacicept, IgA Nephropathy https://novapharmanews.com/uploads/articles/vertex-fda-accepts-bla-povetacicept-iga-nephropathy-accelerated-approval.webp Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy https://novapharmanews.com/us/news/aurobindo-pharma-oai-classification-drug-approvals 2026-06-06T10:10:26.171Z NovaPharmaNews en 2026-06-05T22:12:39.514Z Aurobindo Pharma OAI Classification: Implications for Drug Approvals https://novapharmanews.com/uploads/articles/aurobindo-pharma-oai-classification-drug-approvals.webp Aurobindo Pharma OAI Classification: Implications for Drug Approvals https://novapharmanews.com/us/news/lee-tuberville-introduce-protections-for-homeopathic-medicine-fda-approval-framework 2026-06-06T01:49:41.082Z NovaPharmaNews en 2026-06-05T21:57:44.803Z Lee, Tuberville Introduce Protections for Homeopathic Medicine with FDA Approval Framework https://novapharmanews.com/uploads/articles/lee-tuberville-introduce-protections-for-homeopathic-medicine-fda-approval-framework.webp Lee, Tuberville Introduce Protections for Homeopathic Medicine with FDA Approval Framework https://novapharmanews.com/us/news/daraxonrasib-pancreatic-cancer-survival-2026 2026-06-06T09:02:57.506Z NovaPharmaNews en 2026-06-05T21:00:09.209Z Daraxonrasib Doubles Survival in Pancreatic Cancer: What Pharma Teams Need to Know daraxonrasib, pancreatic cancer https://novapharmanews.com/uploads/articles/daraxonrasib-pancreatic-cancer-survival-2026.webp Daraxonrasib Doubles Survival in Pancreatic Cancer: What Pharma Teams Need to Know https://novapharmanews.com/us/news/fda-approves-ensitrelvir-xocova-first-oral-covid-19-post-exposure-prophylaxis 2026-06-05T22:46:43.403Z NovaPharmaNews en 2026-06-05T20:52:20.223Z FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis ensitrelvir, XOCOVA, COVID-19 https://novapharmanews.com/uploads/articles/fda-approves-ensitrelvir-xocova-first-oral-covid-19-post-exposure-prophylaxis.webp FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis https://novapharmanews.com/us/news/generic-drugmakers-skinny-label-victory-hikma-amarin 2026-06-06T03:09:35.155Z NovaPharmaNews en 2026-06-05T17:52:04.300Z Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case https://novapharmanews.com/uploads/articles/generic-drugmakers-skinny-label-victory-hikma-amarin.webp Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case https://novapharmanews.com/us/news/texas-ag-investigating-energy-drinks-pharma-implications 2026-06-05T22:53:53.992Z NovaPharmaNews en 2026-06-05T15:29:30.329Z Texas AG Investigating Energy Drinks: What Pharma Teams Need to Know https://novapharmanews.com/uploads/articles/texas-ag-investigating-energy-drinks-pharma-implications.webp Texas AG Investigating Energy Drinks: What Pharma Teams Need to Know https://novapharmanews.com/eu/news/myasthenia-gravis-clinical-trial-pipeline-expands-25-companies-delveinsight 2026-06-06T10:07:02.649Z NovaPharmaNews en 2026-06-05T03:14:34.382Z Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates myasthenia gravis https://novapharmanews.com/uploads/articles/myasthenia-gravis-clinical-trial-pipeline-expands-25-companies-delveinsight.webp Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates https://novapharmanews.com/eu/news/mfn-drug-pricing-reshapes-international-life-sciences-licensing-deals 2026-06-06T07:50:46.974Z NovaPharmaNews en 2026-06-05T03:09:13.231Z MFN Drug Pricing Reshapes International Life Sciences Licensing Deals https://novapharmanews.com/uploads/articles/mfn-drug-pricing-reshapes-international-life-sciences-licensing-deals.webp MFN Drug Pricing Reshapes International Life Sciences Licensing Deals https://novapharmanews.com/eu/news/india-oman-cepa-fast-tracks-drug-approvals-cuts-export-barriers 2026-06-06T06:40:26.811Z NovaPharmaNews en 2026-06-05T02:54:41.963Z India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma https://novapharmanews.com/uploads/articles/india-oman-cepa-fast-tracks-drug-approvals-cuts-export-barriers.webp India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma https://novapharmanews.com/us/news/fda-approves-companion-diagnostic-inavolisib-hr-her2-pik3ca-mutated-breast-cancer 2026-06-06T04:53:01.124Z NovaPharmaNews en 2026-06-05T02:32:18.666Z FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer inavolisib, palbociclib, fulvestrant, FoundationOne CDx, FoundationOne Liquid CDx, oncology, breast cancer, HR+/HER2–, PIK3CA-mutated breast cancer, endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer https://novapharmanews.com/uploads/articles/fda-approves-companion-diagnostic-inavolisib-hr-her2-pik3ca-mutated-breast-cancer.webp FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer https://novapharmanews.com/us/news/peptide-reclassification-rfk-jr-fda-announcement-pharmacist-take 2026-06-06T04:31:30.864Z NovaPharmaNews en 2026-06-05T01:39:48.737Z The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means — drug approvals https://novapharmanews.com/uploads/articles/peptide-reclassification-rfk-jr-fda-announcement-pharmacist-take.webp The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means — drug approvals https://novapharmanews.com/apac/news/vietnam-india-middle-power-diplomacy-pharma-market-analysis 2026-06-06T04:09:04.195Z NovaPharmaNews en 2026-06-05T00:37:08.409Z Vietnam and India Reshape Middle Power Diplomacy: Market Analysis for Pharma https://novapharmanews.com/uploads/articles/vietnam-india-middle-power-diplomacy-pharma-market-analysis.webp Vietnam and India Reshape Middle Power Diplomacy: Market Analysis for Pharma https://novapharmanews.com/us/news/scientists-uncover-new-hiding-spot-hiv-bone-marrow 2026-06-06T10:16:19.815Z NovaPharmaNews en 2026-06-05T00:23:35.461Z Scientists uncover a new hiding spot for HIV in bone marrow: Implications for cure research HIV https://novapharmanews.com/uploads/articles/scientists-uncover-new-hiding-spot-hiv-bone-marrow.webp Scientists uncover a new hiding spot for HIV in bone marrow: Implications for cure research